Infinity Pharmaceuticals Inc. buy melinda
Start price
15.06.16
/
50%
€1.55
Target price
15.12.16
€4.51
Performance (%)
-29.74%
End price
15.12.16
€1.09
Summary
This prediction ended on 15.12.16 with a price of €1.09. The price of Infinity Pharmaceuticals Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -29.74%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Infinity Pharmaceuticals Inc. | - | - | - | - |
iShares Core DAX® | -0.448% | 2.344% | 15.948% | 18.098% |
iShares Nasdaq 100 | 0.834% | 5.019% | 30.983% | 56.534% |
iShares Nikkei 225® | -0.479% | 0.550% | 9.206% | 5.013% |
iShares S&P 500 | -0.352% | 2.631% | 26.224% | 46.697% |
Comments by melinda for this prediction
In the thread Infinity Pharmaceuticals Inc. diskutieren
folgen
Infinity Pharmaceuticals veröffentlicht Daten aus der Studie Phase - 2 - Monotherapie duvelisib Unternehmen experimentelle Verbindung Gegenstand der Forschung als mögliche Behandlung für Non-Hodgkin - Lymphom. Diese Studie 129 Patienten wurde in Zusammenarbeit mit dem Kooperationspartner durchgeführt ABBV
(Laufzeit überschritten)
Stopped prediction by melinda for Infinity Pharmaceuticals Inc.
Infinity Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€1.75
02.12.20
02.12.20
€2.00
02.12.21
02.12.21
-6.29%
03.12.21
03.12.21
Infinity Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€1.46
12.11.18
12.11.18
€2.26
12.11.18
12.11.18
-16.36%
12.11.18
12.11.18
Infinity Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.11
19.10.17
19.10.17
€3.11
20.02.18
20.02.18
-21.37%
20.02.18
20.02.18
Infinity Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.34
19.10.17
19.10.17
€3.45
20.02.18
20.02.18
-21.37%
20.02.18
20.02.18
Infinity Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€1.67
15.04.17
15.04.17
€2.62
27.04.17
27.04.17
13.24%
27.04.17
27.04.17